No connection

Search Results

SGRY

BEARISH
$14.0 Live
Surgery Partners, Inc. · NASDAQ
Target $18.8 (+34.3%)
$11.41 52W Range $24.18
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 19, 2026
Market cap
$1.81B
P/E
N/A
ROE
2.8%
Profit margin
-2.4%
Debt/Equity
1.15
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
SGRY exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and deteriorating operational efficiency. While the stock trades at a low Price-to-Sales (0.55) and Price-to-Book (1.05) ratio, these valuation metrics are offset by negative profit margins and a disastrous earnings track record, with 0 beats in the last four quarters. Stagnant revenue growth (2.40%) and aggressive insider selling by the CEO and CFO further undermine the bullish analyst consensus. The combination of a 0/100 technical trend and consistent earnings misses suggests a value trap rather than a value opportunity.

Key Strengths

Low Price-to-Sales ratio (0.55) suggests potential undervaluation of revenue
Price-to-Book ratio of 1.05 indicates the stock is trading near its liquidation value
Positive operating margin (15.09%) shows core business viability before non-operating costs
Healthy liquidity with a current ratio of 1.87 and quick ratio of 1.37
Recent short-term price recovery (+13.3% in 1 month)

Key Risks

Critical financial health failure as evidenced by a Piotroski F-Score of 2/9
Consistent failure to meet earnings expectations (0/4 beats in last 4 quarters)
Negative net profit margins (-2.35%) despite positive operating margins
Stagnant top-line growth (2.40% YoY) in a high-growth sector
Strong bearish insider signal with CEO and CFO selling shares
AI Fair Value Estimate
Based on comprehensive analysis
$12.5
-10.7% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
22
Weak
Value
55
Future
20
Past
15
Health
20
Dividend
0
AI Verdict
High Risk / Fundamental Decay
Key drivers: Piotroski F-Score 2/9, Negative Profit Margins, Insider Selling, Earnings Misses
Confidence
90%
Value
55/100

Trades at a deep discount to sales, but lacks the earnings to justify a higher multiple.

Positives
  • Low P/S (0.55)
  • Low P/B (1.05)
Watchpoints
  • High Forward P/E (36.36) relative to current profitability
Future
20/100

Growth metrics are stagnant and earnings trajectory is downward.

Positives
  • Analyst target price of $18.80
Watchpoints
  • Negligible revenue growth (2.4%)
  • Severe earnings surprise misses (-189.22% avg)
Past
15/100

Long-term trend is aggressively bearish with significant capital erosion.

Positives
  • Historical periods of EPS beats in 2023
Watchpoints
  • 5-Year price change of -67.9%
  • 1-Year price change of -34.0%
Health
20/100

Liquidity is stable, but overall financial health is weak per deterministic scoring.

Positives
  • Current Ratio 1.87
Watchpoints
  • Piotroski F-Score 2/9
  • Debt/Equity 1.15
Dividend
0/100

Non-dividend paying stock.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$14.0
Analyst Target
$18.8
Upside/Downside
+34.3%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for SGRY and closest competitors.

Updated 2026-04-17
SGR
Surgery Partners, Inc.
Primary
5Y
-67.9%
3Y
-63.0%
1Y
-34.0%
6M
-32.0%
1M
+13.3%
1W
+8.4%
EST
Establishment Labs Holdings Inc.
Peer
5Y
-10.1%
3Y
-12.1%
1Y
+127.1%
6M
+54.6%
1M
-10.2%
1W
+5.6%
AZT
Azenta, Inc.
Peer
5Y
-50.6%
3Y
-29.6%
1Y
-26.9%
6M
+16.3%
1M
+16.1%
1W
+0.1%
INV
Innoviva, Inc.
Peer
5Y
+103.6%
3Y
+101.2%
1Y
+39.0%
6M
+37.0%
1M
+6.0%
1W
+3.4%
NTL
Intellia Therapeutics, Inc.
Peer
5Y
-78.8%
3Y
-61.9%
1Y
+103.0%
6M
-42.4%
1M
+11.7%
1W
+7.7%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
36.36
PEG Ratio
N/A
P/B Ratio
1.05
P/S Ratio
0.55
EV/Revenue
2.24
EV/EBITDA
11.3
Market Cap
$1.81B

Profitability

Profit margins and return metrics

Profit Margin -2.35%
Operating Margin 15.09%
Gross Margin 23.12%
ROE 2.76%
ROA 3.74%

Growth

Revenue and earnings growth rates

Revenue Growth +2.4%
Earnings Growth N/A
Q/Q Revenue Growth +2.38%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
1.15
Moderate
Current Ratio
1.87
Good
Quick Ratio
1.37
Good
Cash/Share
$1.87

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.9B
Gross Margin
24.0%
Op. Margin
14.1%
Net Margin
-1.7%
Total Assets
$8.1B
Liabilities
$4.6B
Equity
$1.7B
Debt/Equity
2.68x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
88%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-05
$N/A
2026-03-02
$0.12
-59.5% surprise
2025-11-10
$-0.18
-303.3% surprise
2025-08-05
$-0.02
-204.9% surprise

Healthcare Sector Comparison

Comparing SGRY against 447 companies in the Healthcare sector (26 bullish, 140 neutral, 281 bearish)
Return on Equity (ROE)
2.76%
This Stock
vs
-97.42%
Sector Avg
-102.8% (Below Avg)
Profit Margin
-2.35%
This Stock
vs
-14.95%
Sector Avg
-84.3% (Weaker)
Debt to Equity
1.15
This Stock
vs
3.06
Sector Avg
-62.5% (Less Debt)
Revenue Growth
2.4%
This Stock
vs
147.85%
Sector Avg
-98.4% (Slower)
Current Ratio
1.87
This Stock
vs
4.68
Sector Avg
-60.0% (Weaker)

Similar Companies

Peer comparison within the same industry

SGRY Surgery Partners, Inc.
BEARISH
Mkt Cap
$1.8B
P/E
-
ROE
2.8%
Price
$14.0
ESTA Establishment...
BEARISH
Mkt Cap
$1.8B
P/E
-
ROE
-133.3%
Price
$62.01
 Compare with SGRY
AZTA Azenta, Inc.
NEUTRAL
Mkt Cap
$1.8B
P/E
77.0
ROE
1.4%
Price
$40.05
 Compare with SGRY
INVA Innoviva, Inc.
BULLISH
Mkt Cap
$1.8B
P/E
7.2
ROE
29.1%
Price
$23.76
 Compare with SGRY
NTLA Intellia...
BEARISH
Mkt Cap
$1.8B
P/E
-
ROE
-53.5%
Price
$14.94
 Compare with SGRY

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

EVANS JASON ERIC
Chief Executive Officer
Sell
2026-03-16
20,400 shares · $254,388
DOHERTY DAVID T.
Chief Financial Officer
Sell
2026-03-16
8,867 shares · $110,838
BRITTENHAM MARISSA
Officer
Sell
2026-03-13
3,657 shares · $45,859
BURKHALTER DANIELLE
Officer
Sell
2026-03-13
3,469 shares · $44,507
BALDOCK JENNIFER BOYD
Officer
Sell
2026-03-12
5,798 shares · $76,360
BALDOCK JENNIFER BOYD
Officer
Sell
2026-03-06
10,082 shares · $138,123
EVANS JASON ERIC
Chief Executive Officer
Sell
2026-03-06
11,462 shares · $158,061
DOHERTY DAVID T.
Chief Financial Officer
Sell
2026-03-06
14,574 shares · $201,704
BRITTENHAM MARISSA
Officer
Sell
2026-03-06
8,785 shares · $120,354
BURKHALTER DANIELLE
Officer
Sell
2026-03-06
7,736 shares · $105,210
WEBB WILLIAM TRENTON
Officer
Sell
2026-03-06
2,066 shares · $28,654
BALDOCK JENNIFER BOYD
Officer
Stock Award
2026-03-05
106,307 shares · $1,499,992
EVANS JASON ERIC
Chief Executive Officer
Stock Award
2026-03-05
278,106 shares · $3,924,076
DOHERTY DAVID T.
Chief Financial Officer
Stock Award
2026-03-05
141,743 shares · $1,999,994
BRITTENHAM MARISSA
Officer
Stock Award
2026-03-05
43,230 shares · $609,975
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-03-02

Segra (SGRY) filed an 8-K on March 2, 2026, likely to announce its annual financial results.

10-K
FORM 10-K
2026-03-02

SGRY filed its annual Form 10-K on March 2, 2026. Due to the limited content provided in the excerpts, specific financial highlights and risk factors are not available for summary.

8-K
FORM 8-K
2025-12-16
8-K
FORM 8-K
2025-12-12
8-K
FORM 8-K
2025-12-11
8-K
FORM 8-K
2025-11-12
10-Q
FORM 10-Q
2025-11-10

SGRY filed its Form 10-Q on November 10, 2025. The filing identifies 28 risk factors, although specific financial performance highlights were not provided in the available excerpts.

8-K
FORM 8-K
2025-11-10

Segra filed an 8-K likely to announce its third-quarter financial results for 2025.

8-K
FORM 8-K
2025-09-16
8-K
FORM 8-K
2025-08-13

SGRY filed a Form 8-K on August 13, 2025, likely to announce its second-quarter financial results.

8-K
FORM 8-K
2025-08-06
10-Q
FORM 10-Q
2025-08-05
8-K
FORM 8-K
2025-08-05
8-K
8-K
2025-06-17
8-K
8-K
2025-06-06
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
11 analysts
TD Cowen
2026-03-05
Maintains
Buy Buy
UBS
2026-03-05
Maintains
Buy Buy
Mizuho
2026-03-05
Maintains
Outperform Outperform
RBC Capital
2026-03-04
Maintains
Outperform Outperform
Barclays
2026-03-03
Maintains
Equal-Weight Equal-Weight
Mizuho
2025-12-18
Maintains
Outperform Outperform
JP Morgan
2025-11-24
Maintains
Neutral Neutral
Barclays
2025-11-21
Maintains
Equal-Weight Equal-Weight
Mizuho
2025-11-17
Maintains
Outperform Outperform
UBS
2025-11-13
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning SGRY from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile